Sign Up
Contact

Investors: Overview

Taylored Biotherapeutics

Safe & Effective Microbial Based Therapies

Corporate Profile

Taylored Biotherapeutics is a microbiome therapeutics company focused on the research and development of new drugs to combat a variety of mental health illnesses. By leveraging our robust data platform, sophisticated machine learning technologies and patient-driven developmental pipeline, Taylored is coming up with new solutions for maintaining the well-being of the mind and body.

Taylored has partnered with Netramark, providing proprietary AI to optimize the path in new drug development, accelerate clinical trials, mitigate placebo response, and redefine the landscape of how disorders are treated. Additional partnerships have been made with the University of Calgary’s Innovate Calgary and the Canadian National Research Council’s Industrial Research Assistance Program (NRC-IRAP).

For investment information please contact us at Info@TayloredBio.com

Receive the latest news

Join Our Journey

Be the First to Know: Unlock exclusive updates on the progress and launch timeline of our groundbreaking biotherapeutics product development.

Name(Required)
Close

Asem Bala

MSc

Asem Bala, MSc has over 20 years of experience in Healthcare & Clinical Research Management, now working at Taylored Biotherapeutics to create partnerships and ensure regulatory approvals.

Close

Dr. Valerie Taylor

MD, PhD, FRCP

Dr. Valerie Taylor, MD, PhD, FRCP is a Professor of Psychiatry at the University of Calgary. She completed a Bachelor of Medical Science and graduated from medical school at Memorial University of Newfoundland. She subsequently finished her residency training in Psychiatry and got her PhD in Neuroscience from McMaster University in Hamilton, Ontario. Prior to coming to Calgary, she was the chief of Psychiatry at the Women’s College Hospital and the chief of Adult Health Services at the Center for Addiction and Mental Health in Toronto.

Her academic focus has been on the area of medical psychiatry – specifically, for the last 5 years, on the gut brain axis and the the gut microbiome. She is the only funded researcher in North America examining the therapeutic effects of fecal transplant as a treatment for mental health and she currently has 4 novel clinical trials looking at modifying the gut microbiome to treat mood disorders as well as the largest biological neuroscience microbiome repository in North America. She has over 180 peer reviewed publications and funding from a variety of national and international funding agencies. In 2020 she started Taylored Biotherapeutics, a micro therapeutics drug company. Today her primary role is in leading product development, getting regulatory approval, and finding partnerships.